ArticleClinical drug investigation2026
Economic Evaluation of Axicabtagene Ciloleucel as a Second-Line Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in South Korea: A Cost-Utility Analysis Based on the ZUMA-7 Trial.
Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDiffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in South Korea, with 30-40% of patients relapsing or becoming refractory after first-line therapy. Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy over standard-of-care (SoC) salvage chemotherapy plus autologous stem cell transplantation (ASCT) in the ZUMA-7 trial. While approved for second-line use in South Korea, its cost effectiveness has not yet been evaluated in the local healthcare setting. This study aimed to evaluate the cost effectiveness of axi-cel compared with SoC as a second-line treatment for adult patients with relapsed or refractory DLBCL eligible for ASCT from the perspective of the South Korean healthcare system.
methodsA partitioned survival model with a mixture cure approach was developed based on ZUMA-7 data to compare axi-cel with SoC as second-line treatment for transplant-eligible relapsed/refractory DLBCL. The analysis was conducted from the healthcare system perspective over a lifetime horizon, with costs and outcomes discounted at 4.5% annually. Utilities were estimated from EQ-5D-5L data in ZUMA-7 using the South Korean valuation set. Costs included treatment, subsequent therapies, resource use, adverse event management, and end-of-life care. Deterministic and probabilistic sensitivity analyses were conducted. Cost effectiveness was evaluated using a willingness-to-pay threshold of 1.5-2 times the gross domestic product per capita of South Korea.
resultsOver a lifetime horizon, axi-cel yielded 8.68 life years (LYs) and 7.61 quality-adjusted life years (QALYs) versus 7.10 LYs and 5.91 QALYs for SoC. Total costs were higher for axi-cel, resulting in an incremental cost of KRW 93.9 million (US dollars (USD) 68,676). The incremental cost-effectiveness ratio (ICER) was KRW 55.5 million (USD 40,583) per QALY gained. Sensitivity analyses showed robust results, with subsequent therapy pattern as the most influential parameter.
conclusionsAxi-cel as second-line treatment for relapsed or refractory DLBCL provided meaningful gains in survival and quality-adjusted life and appeared to be a cost-effective alternative compared to SoC in South Korea.
Indexed as
Identifiers
42101810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.